Potential Benefits of Gut Microbiota Transplantation in Parkinson’s Disease

Subin Park^*
*Correspondence: Subin Park, Department of Internal Medicine, Sunchon National University, Suncheon 57922, Korea, Email:

Introduction

Parkinson's Disease (PD) is a complex neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra region of the brain. This leads to motor symptoms such as tremors, rigidity and bradykinesia, along with non-motor symptoms including cognitive impairment, depression and gastrointestinal dysfunction [1]. While the classical hallmark of PD is neuronal dysfunction in the brain, emerging research has highlighted the bidirectional communication between the gut and the brain, emphasizing the role of the gut microbiota in influencing neurological health. Fecal Microbiota Transplantation (FMT), a technique involving the transfer of fecal matter from a healthy donor to a recipient, has gained attention as a potential therapeutic approach for PD due to its capacity to modulate the gut microbiota composition [2]. This paper delves into the current understanding of the gut-brain axis in PD and explores the potential benefits and challenges of utilizing FMT as a novel treatment strategy.

Description

The gut-brain axis refers to the intricate bidirectional communication system linking the Central Nervous System (CNS) and the gastrointestinal tract. This communication occurs through neural, endocrine and immune pathways, with the gut microbiota playing a pivotal role in shaping these interactions. Recent studies have implicated alterations in the gut microbiota composition in the pathogenesis of PD. Alpha-synuclein, a protein implicated in PD, has been found in the enteric nervous system before its appearance in the brain. Additionally, gut dysbiosis and increased intestinal permeability have been observed in PD patients, potentially contributing to the systemic inflammation and neuroinflammation characteristic of the disease. These findings have prompted researchers to explore interventions targeting the gut microbiota, including FMT.

Conclusion

The emerging understanding of the gut-brain axis and its impact on neurological health, particularly in the context of PD, has opened up new avenues for therapeutic interventions. Fecal microbiota transplantation stands out as a promising strategy to target gut dysbiosis, inflammation and potentially mitigate neurodegeneration in PD. While preliminary findings from animal and human studies are encouraging, substantial research is still needed to establish the safety, efficacy and long-term benefits of FMT in PD. The intricate interplay between the gut microbiota, the immune system and the CNS adds complexity to this endeavor, requiring a multidisciplinary approach involving neurology, gastroenterology, microbiology and immunology. As researchers delve deeper into the potential of FMT, there is hope that this innovative approach could one day offer a novel treatment avenue to improve the quality of life for individuals living with Parkinson's disease.

References

1. Armstrong, Melissa J. and Michael S. Okun. "Diagnosis and treatment of Parkinson disease: A review." Jama 323 (2020): 548-560.

Google Scholar, Crossref, Indexed at

2. Cryan, John F., Kenneth J. O'Riordan, Kiran Sandhu and Veronica Peterson, et al. "The gut microbiome in neurological disorders." Lancet Neurol 19 (2020): 179-194.

Google Scholar, Crossref, Indexed at